Analysed PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) News Sources
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?
03-05-2026
yahoo.com
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
04-05-2026
yahoo.com
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
02-06-2026
yahoo.com
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10-06-2026
yahoo.com
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
15-06-2026
yahoo.com
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
16-06-2026
yahoo.com
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
30-06-2026
yahoo.com
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
08-07-2026
yahoo.com
What is the current price of PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ)?
The current price of PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) is $0.444.
PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) absolute price change since previous trading day?
The absolute price change of PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) since the previous trading day is $-0.006.
PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) percentage price change since previous trading day?
The percentage price change of PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) since the previous trading day is -1.3333%.
What is the most recent average sentiment score for PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ)?
The most recent average sentiment score for PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ)?
The most recent sentiment for PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ) is .
SEC-8K** Filing Available For PASITHEA THERAPEUTICS CORP (KTTA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.